March and Q1 2014 IPO Market Review
April 16, 2014 12:50
PM
The March 2014 IPO market produced 23 IPOs—since the end
of 2000, only 10 months have topped the March tally. The 60 IPOs in
the first quarter of 2014 reflect the fourth consecutive quarterly
increase in the number of IPOs and represent the highest quarterly
figure since the 63 IPOs in the fourth quarter of 2007.
Gross proceeds of $2.86 billion in March brought the total for
the first quarter of 2014 to $9.53 billion—71% above the
$5.58 billion raised by the 20 IPOs in the first quarter of
2013.
March produced nine IPOs by life sciences companies, bringing
the year-to-date count to 31 IPOs and equal to 52% of all US IPOs.
The high proportion of life sciences company IPOs is partly
responsible for the decline in the median IPO offering size from
$107.4 million for full year 2013 to $88.0 million in the first
quarter of 2014, representing the lowest yearly figure since the
$84.0 million median offering size in 2000.
The shift in the percentage of profitable IPO companies and the
median annual revenue of IPO companies from 2013 to 2014 is more
stark. The percentage of profitable IPO companies declined from 43%
for full-year 2013 to 22% in the first quarter of 2014—a
figure even below the 26% that prevailed at the height of the
dot-com boom in 1999 and 2000. The median annual revenue of IPO
companies fell from $89.9 million for full-year 2013 to $20.8
million in the first quarter of 2014, with life sciences IPO
companies reporting annual revenue of less than $1 million.
The average IPO company in the first quarter of 2014 has enjoyed
a 21% first-day gain from its offering price—equal to the
average first-day gain for full-year 2013. Year-to-date, 28% of
IPOs were "broken" (closing below the offering price in
first-day trading), representing the highest percentage of broken
IPOs since 2010. At March month-end, a similar percentage of the
2014 IPO class were trading below their offering price. The average
2014 IPO ended the month 27% above its offering price,
outperforming the Dow Jones Industrial Average and Nasdaq Composite
Index by a wide margin.
With 103 IPO public filings in the first three months of
2014—a quarterly total surpassed only once in the prior 10
years—deal flow in the coming months is expected to be strong
as long as favorable capital market conditions prevail. Moreover,
overall deal flow is masked to some extent by confidential
submissions by emerging growth companies under the JOBS Act.
IPO activity in March consisted of offerings by the following
companies listed in the order they came to market:
- Aquinox Pharmaceuticals, a clinical-stage
pharmaceutical company discovering and developing novel drug
candidates to treat inflammation and cancer, priced an IPO upsized
by 14% at the midpoint of the range and gained 9% on its first
trading day.
- Coupons.com, a leading digital promotion
platform that connects great brands and retailers with consumers,
priced an IPO upsized by 5% above the range and produced a
first-day gain of 88%.
- Recro Pharma, a clinical-stage specialty
pharmaceutical company developing non-opioid therapeutics for the
treatment of pain, initially in the post-operative setting, priced
an IPO upsized by 47% below the range and ended its first day of
trading up 4%.
- Achaogen, a clinical-stage biopharmaceutical
company passionately committed to the discovery, development and
commercialization of novel antibacterials to treat multi-drug
resistant, or MDR, gram-negative infections, priced an IPO upsized
by 20% at the low end of the range and traded up 19% on its opening
day.
- Dipexium Pharmaceuticals, a late stage
pharmaceutical company focused on the development and
commercialization of a novel, first-in-class, broad spectrum,
topical antibiotic, priced an IPO upsized by 19% at the low end of
the range and gained 17% on its first day.
- Galmed Pharmaceuticals, a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a novel, once-daily, oral therapy for the
treatment of liver diseases and cholesterol gallstones utilizing
proprietary first-in-class family of synthetic fatty-acid/bile-acid
conjugates, priced an IPO upsized by 21% within the range and ended
its first trading day up 6% from its offering price.
- Castlight Health, a provider of cloud-based
software that enables enterprises to gain control over their
rapidly escalating health care costs, priced above an upwardly
revised price range and produced a first-day gain of 149%—the
fourth "moonshot" of the year (an IPO that doubles in
price on its opening day).
- Paylocity Holding, a cloud-based provider of
payroll and human capital management software solutions for
medium-sized organizations, priced an IPO upsized by 6% above the
range and gained 44% of its first trading day.
- Akebia Therapeutics, a biopharmaceutical
company focused on the development of novel proprietary
therapeutics based on hypoxia inducible factor biology and the
commercialization of these products for patients with kidney
disease, priced an IPO upsized by 20% at the high end of the range
and produced a first-day gain of 57%.
- MediWound, a fully integrated
biopharmaceutical company focused on developing, manufacturing and
commercializing novel products to address unmet needs in the fields
of severe burns, chronic and other hard-to-heal wounds and
connective tissue disorders, priced at the low end of the range and
gained 23% on its first day of trading.
- Q2 Holdings, a leading provider of secure,
cloud-based virtual banking solutions, priced at the top of the
range and gained 17% in first-day trading.
- A10 Networks, a leading provider of advanced
application networking technologies, priced at the top of the range
and gained 8% on its first day of trading.
- Amber Road, provider of cloud-based global
trade management solutions, priced an IPO upsized by 13% above the
range and produced a first-day gain of 31%.
- BorderFree, a market leader in international
cross-border ecommerce, operating a proprietary technology and
services platform to enable U.S. retailers to transact with
consumers in more than 100 countries and territories worldwide,
priced at the top of the range and ended its first day of trading
with a 25% gain.
- Versartis, an endocrine-focused
biopharmaceutical company initially developing a novel long-acting
recombinant human growth hormone, VRS-317, for growth hormone
deficiency, priced an IPO that had earlier been upsized by 30% at
the high end of an upwardly revised price range and jumped 49% in
first-day trading.
- King Digital Entertainment, an interactive
entertainment company for the mobile world with leading games
including Candy Crush Saga, Pet Rescue Saga and Farm Heroes Saga,
priced at the midpoint of the range and slid 16% on its first
day.
- Nord Anglia Education, a leading international
operator of premium schools, priced at the midpoint of the range
and gained 13% on its first day of trading.
- Applied Genetic Technologies, a clinical-stage
biotechnology company that uses its proprietary gene therapy
platform to develop products designed to transform the lives of
patients with severe inherited orphan diseases in ophthalmology,
priced an IPO upsized by 17% below the range and produced a
first-day gain of 23%.
- TriNet Group, a leading provider of a
comprehensive human resources solution for small to medium-sized
businesses, priced in the middle of the range and ended its first
day of trading up 19%.
- 2U, a leading provider of cloud-based
software-as-a-service solutions that enable leading nonprofit
colleges and universities to deliver high quality education to
qualified students anywhere, priced at the high end of the range
and gained 8% on its first day of trading.
- Aerohive Networks, a designer and developer of
a leading cloud-managed mobile networking platform that enables
enterprises to deploy a mobile-centric network edge, priced at the
midpoint of the range and ended its first day flat.
- Energous, a development stage technology
company developing technology that can enable wireless charging or
powering of electronic devices at distance, priced at the expected
price and soared 76% in first-day trading.
- Everyday Health, a leading provider of digital
health and wellness solutions, priced in the middle of the range
and declined 4% on its first day of trading.
Tags: News
|
February 2014 IPO Market Review
March 9, 2014 1:10
PM
The February 2014 IPO market produced 21 IPOs, the third highest
monthly tally since 2007. Life sciences companies dominated the
month with 16 IPOs—76% of the total. Gross proceeds in
February were $1.52 billion, well shy of the $5.15 billion in
January and the lowest monthly figure since February 2013,
reflecting the smaller average size of life sciences offerings.
The average IPO company in the first two months of 2014 has
enjoyed a 16% first-day gain from its offering price—below
the 21% average first-day gain for full-year 2013 but equal to the
average first-day gain for full-year 2012. In the first two months
of 2014, 41% of IPOs were "broken" (IPOs whose stock
closes below the offering price on their opening day)—well
above the 22% for all of 2013. At February month-end, however, only
22% of 2014 IPOs were trading below their offering price—a
figure not much worse than the 19% of 2013 IPOs that ended the year
below their offering price.
The average 2014 IPO ended February 31% above its offering
price, compared to the year-to-date gains of 1% and 6%,
respectively, for the Dow Jones Industrial Average and Nasdaq
Composite Index.
With life sciences companies accounting for approximately 60% of
all IPOs over the first two months of the year, the profile of the
median 2014 IPO is far different than that seen in recent years.
The median offering size of $84.0 million in 2014 is 21% below the
median of $106.7 million for the five-year period of 2009 to 2013.
The percentage of IPO companies that are profitable year-to-date,
at 27%, is equal to half the comparable figure (54%) for IPO
companies between 2009 and 2013. and only a single percentage point
above the 26% figure that prevailed in 1999 and 2000. The median
annual revenue figure of $15.3 million for 2014 IPO companies is
86% below the $106.6 million median for the five-year period of
2009 to 2013 and below even the $17.9 million and $17.6 million
figures in 1999 and 2000, respectively.
IPO activity in February consisted of offerings by the following
companies listed in the order they came to market:
- Auspex Pharmaceuticals, a biopharmaceutical
company focused on the development and commercialization of novel
medicines for the treatment of orphan diseases, priced an IPO
upsized by 17% at the high end of the range and produced a
first-day gain of 31%.
- Biocept, a cancer diagnostics company that
develops and commercializes proprietary circulating tumor cell and
circulating tumor DNA tests utilizing a standard blood sample,
priced an IPO upsized by 5% at the low end of the range and
declined 6% on its first trading day.
- Continental Building Products, a leading, high
margin manufacturer of gypsum wallboard and complementary finishing
products, priced below the range and ended its first day with a
gain of 9%.
- Genocea Biosciences, a clinical stage
biotechnology company that discovers and develops novel vaccines to
address infectious diseases for which no vaccine or vaccines with
limited effectiveness exist today, priced at the low end of the
range and ended its first day of trading down 8% from its offering
price.
- uniQure, a leader in the field of gene therapy
that has developed the first and currently the only gene therapy
product to receive regulatory approval in the European Union,
priced an IPO upsized by 17% above the range and declined 14% on
its first trading day.
- Egalet, a specialty pharmaceutical company
developing and planning to commercialize proprietary,
abuse-deterrent oral products for the treatment of pain and in
other indications, priced an IPO upsized by 20% at the midpoint of
the range and ended its first day flat.
- Eleven Biotherapeutics, a clinical-stage
biopharmaceutical company with a proprietary protein engineering
platform, called AMP-Rx, that the company applies to the discovery
and development of protein therapeutics to treat diseases of the
eye, priced below the range and gained 9% on its first trading
day.
- Ladder Capital, a leading commercial real
estate finance company with a proprietary loan origination platform
and an established national footprint, priced at the midpoint of
the range and ended its first day one cent shy of its offering
price.
- Revance Therapeutics, a clinical stage
specialty biopharmaceutical company focused on the development,
manufacturing and commercialization of novel botulinum toxin
products for multiple aesthetic and therapeutic applications,
priced an IPO upsized by 20% at the high end of the range and
produced a first-day gain of 68%.
- Argos Therapeutics, a biopharmaceutical
company focused on the development and commercialization of fully
personalized immunotherapies for the treatment of cancer and
infectious diseases, priced an IPO upsized by 32% below the range
and ended its first day flat.
- GeoPark, an independent oil and natural gas
exploration and production company with operations in South
America, priced at the low end of its downwardly revised range and
ended its first day of trading down 8%.
- NephroGenex, a pharmaceutical company focused
on the development of therapeutics to treat kidney disease, priced
at the low end of the range and declined 4% on its first trading
day.
- Eagle Pharmaceuticals, a specialty
pharmaceutical company focused on developing and commercializing
injectable products utilizing the FDA's 505(b)(2) regulatory
pathway, priced at the midpoint of the range and ended its first
day 14% below its offering price.
- Flexion Therapeutics, a specialty
pharmaceutical company focused on the development and
commercialization of novel, long-acting, injectable pain therapies,
priced at the midpoint of the range and produced a first-day gain
of 13%.
- Amedica Corporation, a commercial biomaterial
company focused on using their silicon nitride technology platform
to develop, manufacture and sell a broad range of medical devices,
priced below a downwardly revised price range and ended its first
day of trading 6% below its offering price.
- Concert Pharmaceuticals, a clinical stage
biopharmaceutical company applying its extensive knowledge of
deuterium chemistry to discover and develop novel small molecule
drugs, priced an IPO upsized by 20% at the top of the range and
gained 1% on its first day.
- Installed Building Products, the second
largest new residential insulation installer in the United States,
priced below the range and produced a first-day gain of 16%.
- Inogen, a medical technology company that
develops, manufactures and markets innovative portable oxygen
concentrators used to deliver supplemental long-term oxygen therapy
to patients suffering from chronic respiratory conditions, priced
at the low end of the range and declined 5% on its first trading
day.
- Semler Scientific, an emerging medical
risk-assessment company with a product allowing healthcare
providers to measure arterial blood flow in the extremities, priced
below the range and ended its first day one cent shy of its
offering price.
- Lumenis, a provider of innovative
energy-based, minimally invasive clinical solutions, priced below
the range and gained 1% on its first day.
- Varonis Systems, a provider of a software
platform that allows enterprises to map, analyze, manage and
migrate their unstructured data, priced above the range and ended
its first day of trading up 100%—the third
"moonshot" of the year (an IPO that doubles in price on
its opening day).
Tags: News
|
January 2014 IPO Market Review
February 11, 2014 11:46
AM
The 2014 IPO market got off to its earliest start since 1998 as
the inaugural IPO of the year came to market in the first full week
of January. The month ended with 16 IPOs—only one shy of the
combined January IPO total over the preceding three years, and the
highest January tally since the 20 IPOs in January 2000. The last
day of January alone produced six IPOs—a daily count that
high seen only three times since the end of 2000.
Continuing a trend from 2013, the life sciences sector produced
the largest number of IPOs in the month, with six. Energy-related
companies contributed five IPOs in January.
Gross proceeds of $5.15 billion for January were 57% higher than
the $3.29 billion for the corresponding month in 2013. The largest
January 2014 IPO was the $1.80 billion offering by Santander
Consumer US, followed by offerings from oil and gas companies Rice
Energy ($924 million) and EP Energy ($704 million).
The average January IPO saw a first day gain of 25% compared to
the 21% first-day gain for the average IPO in 2013, but the 2014
figure was buoyed by two "moonshots" (an IPO that doubles
in price on its opening day). Without the IPOs of Dicerna
Pharmaceuticals and Ultragenyx Pharmaceutical, which enjoyed
first-day gains of 207% and 102%, respectively, the average
first-day gain for IPOs in January would have been only 7%.
The average life sciences IPO in January saw a first-day gain of
56%—but only 6% without the two moonshots. The five
energy-related IPOs in January declined an average of 2% on their
first day of trading.
January's median offering size of $110.5 million was 3%
above the full-year 2013 figure of $107.4 million. Emerging growth
companies in January had a median offering size of $90.5 million
compared to the $814.0 million median deal size for non-EGC
companies. The median offering size for venture-backed companies,
based on a small sample size of seven IPOs in the month—was
only $64.8 million in January.
The percentage of profitable IPO companies declined from 43% in
full-year 2013 to 38% in January 2014.
IPO activity in January consisted of offerings by the following
companies listed in the order they came to market:
- GlycoMimetics, a clinical stage biotechnology
company focused on the discovery and development of novel
glycomimetic drugs to address unmet medical needs resulting from
diseases in which carbohydrate biology plays a key role, priced an
IPO upsized by 22% at the estimated offering price and ended its
first day with a 13% gain.
- CHC Group, the world's largest commercial
operator of heavy and medium helicopters, priced an IPO upsized by
5% below a downwardly revised price range and declined 2% on its
first trading day.
- EP Energy, an independent exploration and
production company engaged in the acquisition and development of
unconventional onshore oil and natural gas properties in the United
States, priced a downsized IPO below the range and ended its first
day 10% below its offering price.
- RSP Permian, an independent oil and natural
gas company focused on the acquisition, exploration, development
and production of unconventional oil and associated liquids-rich
natural gas reserves in the Permian Basin of West Texas, priced
within the range and saw a first-day gain of 3%.
- Santander Consumer USA, a full-service,
technology-driven consumer finance company focused on vehicle
finance and unsecured consumer lending products, priced an IPO
upsized by 15% at the low end of an upwardly revised price range
and gained 5% on its first day.
- Rice Energy, an independent natural gas and
oil company engaged in the acquisition, exploration and development
of natural gas and oil properties in the Appalachian Basin, priced
an IPO upsized by 10% at the high end of the range and ended its
first trading day up 4%.
- Care.com, the world's largest online
marketplace for finding and managing family care, priced above the
range and saw a first-day gain of 43%.
- North Atlantic Drilling, an offshore drilling
company focused on operations in the North Atlantic Region, priced
at the mid-point of the range and declined 8% on its first
day.
- Celladon, a clinical-stage biotechnology
company applying its leadership position in the field of calcium
dysregulation by targeting SERCA enzymes to develop novel therapies
for diseases with unmet medical needs, priced an IPO upsized by 10%
at the estimated offering price and ended its first day with a 2%
gain.
- Dicerna Pharmaceuticals, a biopharmaceutical
company focused on the discovery and development of innovative
treatments for rare inherited diseases involving the liver and for
cancers that are genetically defined, priced above expectations and
gained 207% on its first day of trading. Only one IPO since 2000
has enjoyed a higher first-day gain.
- Cara Therapeutics, a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pain by selectively
targeting kappa opioid receptors, priced at the low end of the
range and ended its first day up 17%.
- Intrawest Resorts Holdings, a North American
mountain resort and adventure company, priced below the range and
declined 1% on its first day.
- Malibu Boats, a leading designer, manufacturer
and marketer of performance sport boats, priced at the midpoint of
the range and ended its first day with a 27% gain.
- The New Home Company, a new generation
homebuilder focused on the design, construction and sale of
innovative and consumer-driven homes in major metropolitan areas
within select growth markets in California, priced below the range
and gained 11% on its first trading day.
- Trevena, a clinical stage biopharmaceutical
company that discovers, develops and intends to commercialize
therapeutics that use a novel approach to target G protein coupled
receptors, priced an IPO upsized by 9% at the expected price and
ended its first day down 7% from its offering price.
- Ultragenyx Pharmaceutical, a development-stage
biopharmaceutical company focused on the identification,
acquisition, development, and commercialization of novel products
for the treatment of rare and ultra-rare diseases, with an initial
focus on serious, debilitating metabolic genetic diseases, priced
an IPO upsized by 19% above the range and saw a first-day gain of
102%.
Tags: News
|
December and 2013 Year-End IPO Market
Review
January 29, 2014 4:25
PM
The IPO market regained some of its luster in 2013. Highlights
for the year included:
- The year produced 178 IPOs—the third highest annual total
since 2000, trailing only the 198 IPOs in 2004 and 193 IPOs in
2007.
- The final three quarters of 2013 each produced 50 or more
IPOs—a level of consistently high activity not seen since
2000.
- The six billion-dollar IPOs in 2013 represented the highest
annual tally since 2004, when there were seven billion-dollar
IPOs.
- The 21% average first-day gain in 2013 was the best annual
figure since the 53% average first-day gain in 2000.
- There were six "moonshots" (an IPO that doubles in
price on its opening day) in 2013. The 12-year period from 2001 to
2012 produced a total of only 11 moonshots, with no single year
seeing more than a pair.
- The average year-end gain of 47% for all IPOs in 2013 was the
highest annual figure since the dot-com era.
From 2003 to 2012, December was on average the second busiest
month for IPOs, trailing only November. On the heels of three
consecutive months with at least 20 IPOs, the December 2013 IPO
market produced only 11 IPOs—the lowest monthly total since
April 2013 but only two IPOs below the December average over the
preceding 10 years.
Gross proceeds of $4.37 billion for December were lifted by
Hilton's $2.35 billion IPO—the largest IPO of 2013. The
year's gross proceeds of $41.27 billion were 18% above the 2012
total of $35.11 billion and the second highest annual level since
2000, behind only the $43.33 billion in 2007.
The 2013 IPO market was dominated by emerging growth companies
(EGCs), which produced 82% of all IPOs—slightly higher than
the 76% market share for EGC IPOs in 2012 following the enactment
of the JOBS Act in April 2012.
The number of IPOs by venture capital–backed US issuers
increased 39%, from 51 in 2012 to 71 in 2013—a single IPO
below the post-boom peak of 72 in 2007. The number of IPOs by
private equity–backed US issuers increased by 75%, from 28 in
2012 to 49 in 2013—only three below the 52 in 2006 (the
highest tally since at least 1996). VC-backed and PE-backed company
IPOs accounted for 50% and 35%, respectively, of all US-issuer IPOs
in 2013.
December capped the year with three life sciences IPOs, bringing
the year's total to 50—28% of all IPOs, and seven more
than the aggregate of 43 life sciences IPOs in the three years
between 2010 and 2012.
The average IPO company enjoyed a 21% first-day gain from its
offering price in 2013, surpassing the 16% average first-day gain
for all IPOs in 2012. The percentage of "broken" IPOs
(IPOs whose stock closes below the offering price on their opening
day) rose from 20% in 2012 to 22% in 2013 but still represented the
second lowest percentage of broken IPOs since 2006.
The average 2013 IPO ended the year 47% above its offering price
compared to the year-end gains of 26%, 38% and 30%, respectively,
for the Dow Jones Industrial Average, Nasdaq Composite Index and
S&P 500.
The median offering size of $107.4 million in 2013 was 14%
higher than the median offering size of $94.3 million in 2012. The
median deal size for VC-backed companies was $78.0
million—the lowest level since the $72.0 million median in
2006—while the median deal size for non-VC backed companies
was $226.7 million, 55% higher than the prior 10-year average of
$146.0 million. The median deal size for EGCs, at $95.9 million,
was less than a quarter of the $419.1 million median deal size for
other IPO companies.
The median annual revenue of IPO companies decreased by
one-third, from $133.6 million in 2012 to $89.9 million in
2013—the lowest level since the $74.5 million median in 2007.
Emerging growth companies had median annual revenue of $61.5
million compared to $2.54 billion for other companies. Median
annual revenue for EGCs in 2013 was down 43% from the $107.8
million in 2012, in part due to the higher number of life sciences
IPOs. Life sciences IPO companies in 2013 had median annual revenue
of just $10.0 million, although this was more than quadruple the
$2.4 million figure over the prior three-year period.
With interest rates at historic lows and investors more eager
for growth than profitability, the percentage of profitable IPO
companies declined from 55% in 2012 to 43% in 2013—the lowest
level since the 26% in both 1999 and 2000. Only 27% of this
year's life sciences and technology related IPO companies were
profitable.
IPO activity in December consisted of offerings by the following
companies listed in the order they came to market:
- Xencor, a clinical-stage biopharmaceutical
company focused on discovering and developing engineered monoclonal
antibodies to treat severe and life-threatening diseases with unmet
medical needs, priced an upsized IPO at a lower revised price and
produced a first-day gain of 52%.
- Kofax, a leading provider of smart process
applications software and related maintenance and professional
services, priced within the range and ended its first day with a
gain of 14%.
- Autohome, the leading online destination for
automobile consumers in China, priced above an upwardly revised
price range and gained 77% on its first day.
- ARAMARK, a leading global provider of food,
facilities and uniform services to education, healthcare, business
and industry and sports, leisure and corrections clients, priced at
the low end of the range and saw a first-day gain of 14%.
- Hilton Worldwide, one of the largest and
fastest growing hospitality companies in the world, priced an IPO
upsized by 4% within the range and ended its first day of trading
up 8%.
- Kindred Biosciences, a development-stage
biopharmaceutical company focused on saving and improving the lives
of pets, priced an IPO upsized by 30% at the midpoint of the range
and gained 71% on its opening day.
- Scorpio Bulkers, an international shipping
company operating the latest generation of dry bulk carriers, more
than doubled the number of shares offered and declined 3% on its
first trading day.
- TetraLogic Pharmaceuticals, a clinical-stage
biopharmaceutical company focused on discovering and developing
novel small molecule therapeutics, priced an IPO upsized by 10% at
the estimated offering price and ended its first day flat.
- Fidelity & Guaranty Life, a provider of
fixed annuities and life insurance products, priced at the low end
of the range and gained 11% on its opening day.
- Nimble Storage, which has designed and sells a
flash-optimized hybrid storage platform, priced above the range and
ended its first trading day with a gain of 62%.
- AMC Entertainment, one of the world's
largest theatrical exhibition companies, priced at the low end of
the range and saw a first-day gain of 5%.
Tags: News
|
November 2013 IPO Market Review
December 3, 2013 12:15
PM
The November IPO market produced 24 IPOs—the highest
monthly count for 2013 and the second highest number of November
IPOs since 1999, lagging only the 28 IPOs in November 2006. The
November 2013 total was also the eighth highest number of IPOs for
any calendar month since the end of 2000.
In the 12-year period from 2001 to 2012, there were a total of
only 14 weeks with 10 or more IPOs. The first week of November saw
11 IPOs—the highest weekly number of IPOs since November 2007
and the third week in 2013 with a double-digit IPO count.
The first 11 months of 2013 have produced 167 IPOs, 64% more
than the 102 IPOs in full-year 2012, and two IPOs above the
January–November average of 165 IPOs recorded between 2004
and 2007—a period with an annual average of 186 IPOs.
Gross proceeds of $5.28 billion for November represented the
second highest monthly figure for 2013, reflecting the month's
high IPO count but also buoyed by Twitter's $1.82 billion IPO
and large offerings from Extended Stay America ($565 million) and
Avianca Holdings ($409 million). Year-to-date gross proceeds of
$36.90 billion are now 5% above the 2012 full-year total of $35.11
billion and the highest level since the $43.33 billion for
full-year 2007.
The IPO market remains dominated by emerging growth companies
(EGCs), which produced 83% of all IPOs in the first 11 months of
2013—slightly higher than the 76% market share for EGC IPOs
in 2012 following the enactment of the JOBS Act in April 2012.
VC-backed and PE-backed company IPOs accounted for 40% and 31%,
respectively, of all IPOs in the first 11 months of the year.
Despite seven life sciences IPOs being postponed in the month,
November produced four life sciences IPOs, bringing the
year-to-date total to 47—28% of all IPOs and four more than
the total of 43 life sciences IPOs in the three-year period between
2010 and 2012.
The average IPO company in the first 11 months of 2013 has
enjoyed a 21% first-day gain from its offering
price—surpassing the 16% average first-day gain for full-year
2012. In this period, 23% of IPOs were "broken," the
second lowest percentage of broken IPOs since 2007 and behind only
the 20% in all of 2012. November IPOs faced a stiffer headwind
compared to IPO earlier in the year, with an average first day gain
of 16% and eight of the month's IPO (33%) ending below their
offer price on their first day.
The average 2013 IPO ended the month 36% above its offering
price, compared to the year-to-date gains of 23% and 34%,
respectively, for the Dow Jones Industrial Average and Nasdaq
Composite Index.
The year-to-date median offering size of $106.0 million is 12%
above the full-year 2012 figure of $94.3 million. The median deal
size for VC-backed companies was $78.4 million—the lowest
level since the $72.0 million median in 2006—while the median
deal size for non-VC backed companies was $222.2 million, 52%
higher than the prior 10-year average of $146.0 million. The median
deal size for emerging growth companies, at $96.4 million, was less
than a quarter of the $419.1 million median deal size for other IPO
companies.
The median annual revenue of IPO companies decreased by a third,
from $133.6 million in 2012 to $89.1 million in the first 11 months
of 2013—the lowest level since the $74.5 million median in
2007. Emerging growth companies had median annual revenue of $63.8
million compared to $2.36 billion for other companies. Life
sciences IPO companies in the first 11 months of the year had
median annual revenue of just $10.6 million.
With interest rates at historic lows and investors more eager
for growth potential than profitability, the percentage of
profitable IPO companies has declined from 55% in 2012 to 43% in
2013—the lowest level since the 26% in both 1999 and 2000.
Only one-fourth of this year's life sciences and technology
related IPO companies were profitable.
November IPO activity consisted of offerings by the following
companies listed in the order they came to market:
- Panama-based Avianca Holdings, a leading
airline in Latin America, priced below the range and ended its
first day 7% below its offering price.
- Barracuda Networks, a provider of
cloud-connected security and storage solutions, priced at the low
end of the range and saw a first-day gain of 20%.
- Blue Capital Reinsurance Holdings, a Bermuda
reinsurance holding company seeking primarily to offer
collateralized reinsurance in the property catastrophe market,
priced at the estimated offering price and ended its first day down
6%.
- Karyopharm Therapeutics, a clinical-stage
pharmaceutical focused on the discovery and development of novel
first-in-class drugs directed against nuclear transport targets for
the treatment of cancer and other major diseases, priced an IPO
upsized by 20% at the high end of the range and ended its first day
slightly above its offering price.
- Wix.com, a leading global web development
platform, priced at the high end of the range and declined 1% on
its first day.
- LGI Homes, a homebuilder engaged in the design
and construction of entry-level homes in Texas, Arizona, Florida
and Georgia, priced below the range and saw a first-day gain of
13%.
- Mavenir Systems, a leading provider of
software-based telecommunications networking solutions, priced
below the range and ended its first day down 4%.
- Norcraft Companies, a leading manufacturer of
kitchen and bathroom cabinetry in the US and Canada, priced an IPO
upsized by 9% at the low end of the range and saw a first-day loss
of 3%.
- Twitter, a global platform for public
self-expression and conversation in real time, priced above the
range and ended its first trading day up 73%.
- JGWPT Holdings, a leading direct response
marketer that provides liquidity to its customers by purchasing
structured settlement, annuity and lottery payment streams in the
United States, priced below the range and declined 8% on its first
day.
- NMI Holdings, a provider of private mortgage
insurance in the United States, priced at the high end of the range
and saw a first-day gain of 8%.
- Chegg, a leading student-first connected
learning platform, priced above the range and declined 23% on its
first day.
- Eros International, a leading global company
in the Indian film entertainment industry, priced a downsized IPO
below the range and ended its first day down 1%.
- Extended Stay America, the largest owner and
operator of company-branded hotels in North America, priced within
the range and saw a first-day gain of 19%.
- Houghton Mifflin Harcourt, a leading global
provider of education solutions, priced below the range and gained
32% on its first day.
- Tandem Diabetes Care, a medical device company
with an innovative approach to the design, development and
commercialization of products for people with insulin-dependent
diabetes, priced an IPO upsized by 12% at the high end of the range
and ended its first day with a 28% gain.
- Relypsa, a pharmaceutical company focused on
the development and commercialization of non-absorbed polymeric
drugs to treat disorders in the areas of renal, cardiovascular and
metabolic diseases, priced below the estimated offering price and
saw a first-day gain of 10%.
- zulily, a flash sales site launched with the
goal of revolutionizing the way moms shop for children's
apparel and other products, priced above an upwardly revised range
and gained 71% on its first day.
- Evogene, a plant genomics company that uses a
comprehensive and integrated technology infrastructure to enhance
seed traits underlying crop performance and productivity, gained
17% on its first day.
- Navigator Holdings, the owner and operator of
the world's largest fleet of handysize liquefied gas carriers,
priced an upsized IPO at the high end of the range and saw a first
day-gain of 20%.
- 500.com, a leading online sports lottery
service provider in China, priced at the high end of an upwardly
revised price range and gained 54% on its first day.
- Oxford Immunotec, a global, commercial-stage
diagnostics company committed to improving patient care by
providing advanced, innovative tests in the field of immunology,
priced below the range and ended its first day up 28%.
- Sungy Mobile, a leading provider of mobile
internet products and services globally with a focus on
applications and mobile platform development, priced within the
range and saw a first-day gain of 19%.
- Vince, a diversified apparel company that
designs, manufactures, and markets a collection of fashion brands,
priced above the range and gained 43% on its first day.
Tags: News
|
October 2013 IPO Market Review
November 18, 2013 10:50
AM
Despite the government shutdown and uncertainty regarding the
debt ceiling, the IPO market produced 22 IPOs in
October—eight more than the 14 IPOs in October 2012 and the
highest number for any month since the 24 IPOs in November 2007.
Filing activity also appears not to have been impeded, with IPO
filings in the month equal to September's total and the highest
October total since 2000.
The October IPO count brings the year-to-date total to 143 IPOs,
40% higher than the 102 IPOs in full-year 2012, and a single IPO
behind the January–October average of 144 IPOs recorded
between 2004 and 2007—a period with an annual average of 186
IPOs.
October's gross proceeds of $5.79 billion was the highest
monthly figure for 2013 and the fifth highest monthly figure since
the start of 2008. Year-to-date gross proceeds of $31.62 billion
now trail the $34.15 billion gross proceeds through the first 10
months of 2012 by only 7%—the 2012 figure buoyed by
Facebook's $16.0 billion offering.
Emerging growth companies (EGCs) continue to dominate the IPO
market, accounting for 83% of all IPOs through
October—slightly higher than the 76% market share claimed by
EGC IPOs last year, following the enactment of the JOBS Act in
April 2012.
The "moonshots" (an IPO that doubles in price on its
opening day) by The Container Store, Potbelly and Voxeljet bring
the 2013 count to six. The three were up 101%, 120% and 122%,
respectively, on their first day—the second, third and sixth
best first-day gains of the year. No other year has seen more than
a pair of moonshots since the tally of 85 in 2000, and there have
been a total of only 11 moonshots in the intervening years. The
average IPO company in the first 10 months of 2013 has enjoyed a
22% first-day gain from its offering price—surpassing the 16%
average first-day gain for full-year 2012. In this period, 22% of
IPOs were "broken" (IPOs whose stock closes below the
offering price on their opening day), compared to 20% in all of
2012, but this percentage still represents the second-lowest level
of broken IPOs since 2007.
At the end of October, the average 2013 IPO company was trading
39% above its offering price and 32% of the year's IPOs were
trading at least 50% above their offering price. Overall, 75% of
the year's IPOs were trading above their offering price at
October month-end.
The median deal size for October IPOs of $222.5 million was more
than twice the year-to-date median of $105.0 million—partly
explaining the high gross proceeds for the month. The year-to-date
median offering size is 11% above the full-year 2012 figure of
$94.3 million. The median deal size for VC-backed companies was
$78.4 million—the lowest level since the $72.0 million median
in 2006—while the median deal size for non-VC backed
companies was $230.0 million, 58% higher than the prior 10-year
average of $146.0 million.
The median annual revenue of IPO companies in 2013 remains well
below the 2012 level, reflecting the higher percentage of emerging
technology and life sciences companies going public. Median annual
revenue decreased by a third, from $133.6 million in 2012 to $89.1
million in the first 10 months of 2013—the lowest level since
the $74.5 million median in 2007. Life sciences IPO companies in
the first 10 months of the year had median annual revenue of just
$11.6 million. EGCs completing IPOs had median annual revenue of
$63.6 million, compared to $2.48 billion for other companies.
The percentage of profitable companies going public declined
from 55% in 2012 to 43% in the first 10 months of 2013—the
lowest level since the 26% in both 1999 and 2000.
October IPO activity consisted of offerings by the following
companies listed in the order they came to market:
- Burlington Stores, a national off-price
retailer of high quality branded apparel, priced above the range
and ended its first day with a 47% gain.
- RE/MAX Holdings, one of the world's
leading franchisors of real estate brokerage services, priced above
the range and saw a first-day gain of 23%.
- Potbelly, a fast-growing neighborhood sandwich
concept offering toasty warm sandwiches, signature salads and other
fresh menu items, priced above the range and soared 120% on its
first day.
- LDR Holding, a global medical device company
focused on designing and commercializing novel and proprietary
surgical technologies for the treatment of patients suffering from
spine disorders, priced within the range and gained 29% on its
first day.
- SFX Entertainment, a producer of live events
and entertainment content focused exclusively on the electronic
music culture, priced an IPO upsized by 20% at the top end of the
range and saw a first-day loss of 9%.
- Antero Resources, an independent oil and
natural gas company, priced an IPO upsized by 19% above the range
and ended its first day with a gain of 18%.
- MacroGenics, a biopharmaceutical company
focused on discovering and developing innovative monoclonal
antibody-based therapeutics for the treatment of cancer and
autoimmune diseases, priced an IPO upsized by 25% at the top of the
range and gained 56% in first-day trading.
- Stonegate Mortgage, a non-bank, integrated
mortgage company, pricing a downsized IPO below the range and saw a
first-day gain of 14%.
- Consumer finance company Springleaf Financial
priced an upsized IPO at the high end of the range and gained 13%
on its first day.
- Veeva Systems, a provider of
industry-specific, cloud-based software solutions for the life
sciences industry, priced above an upwardly revised range and ended
its first day up 86%.
- Germany-based Voxeljet, a provider of
high-speed, large-format 3D printers and on demand parts services,
priced at the low end of the range and jumped 122% on its first
day—the first company since 1999 to double on its first day
after pricing at the low end of its range.
- Aerie Pharmaceuticals, a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with glaucoma and other diseases of the eye, priced an IPO
upsized by 28% below the range and saw a first-day gain of 6%.
- CommScope Holding, a global provider of
connectivity and essential infrastructure solutions for wireless,
business enterprise and residential broadband networks, priced
below the range and ended its first day one cent shy of its
offering price.
- Endurance International Group, a provider of
cloud-based solutions designed to help small- and medium-sized
businesses, establish, manage and grow their businesses, priced
below the range and declined 6% on its first day.
- Paris-based Criteo, an ad tech company that
enables e-commerce companies to leverage large volumes of granular
data to efficiently and effectively engage and convert their
customers, priced an IPO upsized by 12% above an upwardly revised
price range and saw a first-day gain of 14%.
- Surgical Care Affiliates, an operator of one
of the largest networks of outpatient surgery facilities in the
United States, priced at the top of the range and ended its first
day up 13% from its offering price.
- Veracyte, a diagnostics company pioneering the
field of molecular cytology to improve patient outcomes and lower
healthcare costs, priced an IPO upsized by 6% at the low end of the
range and saw a first-day gain of 2%.
- 58.com, an online marketplace serving local
merchants and consumers in China, priced above an upwardly revised
price range and ended its first day up 42%.
- Essent Group, a private mortgage insurance
company, priced above the range and saw a first-day gain of
26%.
- Marcus & Millichap, a national brokerage
firm specializing in commercial real estate investment sales,
financing, research and advisory services, priced below the range
and ended its first day with a 12% gain.
- Qunar, the leading search-based commerce
platform for the travel industry in China, priced above the range
and saw a first-day gain of 89%.
- The Container Store Group, the leading
specialty retailer of storage and organization products in the
United States, priced at the top end of an upwardly revised range
and ended its first day up 101%.
Tags: News
|
September and Q3 2013 IPO Market Review
October 21, 2013 3:25
PM
The 2013 IPO market saw the largest number of September IPOs
since 2000, ending the month with 20 IPOs—the second highest
monthly total since the end of 2010—despite being dormant in
the two weeks following Labor Day. The month's total was triple
the September average over the past 10 years.
The IPO market has produced 121 IPOs during the first three
quarters of 2013—39 more (48%) than the 82 IPOs completed in
the first three quarters of 2012 and nine more than the annual
average of 112 IPOs that has prevailed for the past three years.
The year-to-date 2013 total is only four IPOs below the average
January–September tally recorded between 2004 and
2007—a period with an annual average of 186 IPOs.
With gross proceeds of $3.27 billion in September, the
year-to-date IPO proceeds of $25.83 billion trail the $30.60
billion of proceeds in the first three quarters of 2012, a drop
largely due to the inclusion of Facebook's $16.0 billion
offering in the 2012 tally.
Emerging growth companies (EGCs) continue to dominate the IPO
market, accounting for 82% of all IPOs in the first three quarters
of 2013—slightly higher than the 76% market share claimed by
EGC IPOs last year, following the enactment of the JOBS Act in
April 2012.
There were 53 venture-backed US issuer IPOs (44% of the total)
in the first three quarters of 2013, compared to 41 in the first
three quarters of 2012 (50% of the total) and 51 for all of 2012
(50% of the year's total).
The market's appetite for life sciences companies continued
unabated with eight life sciences IPOs in the month. The first nine
months of 2013 have now seen 39 IPOs by life sciences
companies—blowing by the full-year total of 14 in both 2011
and 2012. While talk of a "biotech IPO bubble" remains
and some life sciences companies have priced upsized IPOs above the
price range, others have been forced to slash their deal size and
price range, indicating the market remains selective and is
assessing the value of each IPO on its individual merits.
With private equity–backed IPOs performing well in the
aftermarket and private equity firms eager to achieve liquidity for
their portfolio companies, the number of PE-backed IPOs jumped to
38 in the first three quarters of 2013 (32% of the total)—10
more than the full-year 2012 total (28% of all 2012 IPOs).
Overall, technology and life sciences companies have accounted
for 65% of the year's IPOs thus far, up from 58% for full-year
2012 and the highest percentage since the end of the dot-com bubble
in 2000.
September saw the third, fourth, fifth and sixth best first-day
gains of the year and only four IPOs were "broken" (IPOs
whose stock closes below the offering price on their opening day).
The average IPO company in the first three quarters of 2013 enjoyed
a 19% first-day gain from its offering price—eclipsing the
16% average first-day gain for full-year 2012. In the first three
quarters of 2013, 37 companies—31% of the
total—produced a first-day gain of at least 25%. In this
period, 23% of IPOs were "broken", compared to 20% in all
of 2012, but this percentage still represents the second-lowest
level of broken IPOs since 2007.
At the end of September, the average 2013 IPO company was
trading 44% above its offering price and 36% of the year's IPOs
were trading at least 50% above their offering
price—including 13% that were up more than 100% from their
offering price. Overall, 77% of the year's IPOs were trading
above their offering price as of September 30.
The median deal size of $101.2 million for the first three
quarters of 2013 was 7% higher than the $94.3 million median in
full-year 2012. The median deal size for VC-backed companies was
$77.5 million—the lowest level since the $72.0 million median
in 2006—while the median deal size for non-VC backed
companies was $226.1 million, 55% higher than the prior 10-year
average of $146.0 million. The median deal size for EGCs, at $81.6
million, was less than a fifth of the $436.3 million median deal
size for other companies.
The median annual revenue of IPO companies in 2013 remains well
below the 2012 level, in part due to the high percentage of life
sciences companies going public. Median annual revenue decreased
39%, from $133.6 million in 2012 to $81.7 million in the first
three quarters of 2013, representing the lowest level since the
$74.5 million median in 2007. Life sciences IPO companies in the
first three quarters of the year had median annual revenue of just
$10.6 million. EGCs completing IPOs had median annual revenue of
$53.7 million, compared to $2.36 billion for other companies.
The percentage of profitable companies going public declined
from 55% in 2012 to 42% in the first three quarters of
2013—the lowest level since the 26% in both 1999 and 2000.
With investor focus shifting to growth over profitability, only 26%
of this year's life sciences and technology-related IPO
companies were profitable.
September IPO activity consisted of offerings by the following
companies listed in the order they came to market:
- BenefitFocus, a private equity–backed
provider of an integrated suite of cloud-based benefits software
solutions for consumers, employers, insurance carriers and brokers,
priced an IPO upsized by almost 10% above the range and saw a
first-day gain of 102%.
- Five Prime Therapeutics, a clinical-stage
biotechnology company focused on discovering and developing novel
protein therapeutics, antibodies or drugs developed from
extracellular proteins or protein fragments that block disease
processes, including cancer and inflammatory diseases, priced an
IPO upsized by 20% within the range and gained 1% on its first
day.
- Volaris Aviation Holding, a low-cost airline
based in Mexico, priced at the low end of the range and traded up
17% on the first day.
- Acceleron Pharma, a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel protein therapeutics for cancer and rare
diseases, priced an IPO upsized by 20% at the top of the range and
ended its first day of trading up 33%.
- Bind Therapeutics, a clinical-stage
nanomedicine platform company developing targeted and programmable
therapeutics, priced in the middle of the range and saw a first-day
gain of less than 1%.
- ClubCorp Holdings, a membership-based leisure
business and a leading owner-operator of private golf, country,
business, sports and alumni clubs in North America, priced below
the range and increased 4% in first-day trading.
- FireEye, a provider of a virtual machine-based
security platform that provides real-time protection to enterprises
and governments worldwide against cyber-attacks, priced an upsized
IPO above an already upwardly revised price range and enjoyed a
first-day gain of 80%.
- Rocket Fuel, a provider of an artificial
intelligence and big data–driven predictive modeling and
automated decision-making platform, priced at the high end of an
upwardly revised range and jumped 93% in first-day trading.
- Evoke Pharma, a specialty pharmaceutical
company focused primarily on the development of drugs to treat
gastrointestinal disorders and diseases, priced at the low end of
the range and traded down 2% on its first day.
- Foundation Medicine, a provider of a molecular
information platform for analyzing tumor tissue samples across all
types of cancer, priced an IPO upsized by 18% above the range and
soared 96% in first-day trading.
- Ophthotech, a biopharmaceutical company
specializing in the development of novel therapeutics to treat
diseases of the eye, priced an IPO upsized by 33% above an upwardly
revised price range and ended its first day up 20%.
- Applied Optoelectronics, a vertically
integrated provider of fiber-optic networking products for cable
television, fiber-to-the-home and internet data centers, priced
below the range and saw a first-day loss of less than 1%.
- Covisint Corporation, a provider of a cloud
engagement platform for enabling organizations to securely connect,
engage and collaborate with large, distributed communities of
customers, business partners and suppliers, priced within the range
and traded up 23% on the first day.
- Montage Technology Group, a global fabless
provider of analog and mixed-signal semiconductor solutions
currently addressing the home entertainment and cloud computing
markets, priced below the range and saw a first-day gain of
28%.
- Premier, a national healthcare alliance,
priced above the range and gained 14% on its first day.
- Enzymotec, a biotechnology company that
develops and produces biofunctional ingredients to address health
needs associated with the human life cycle, priced below the range
and ended its first day up 30%.
- Pattern Energy Group, an independent power
company focused on owning and operating power projects, priced
above the range and saw a first-day gain of 6%.
- RingCentral, a provider of
software-as-a-service solutions for business communications, priced
at the top end of the range and ended its first day up 40%.
- Violin Memory, a provider of flash-based
memory storage solutions, priced in the middle of the range and
declined 22% on its first day.
Despite the Federal Reserve's decision not to scale back its
bond-buying program, the recent government shutdown and political
brinkmanship over raising the country's debt limit that ended
with only a short-term solution suggests there may be some market
turbulence on the horizon. The currently robust pipeline, however,
points to an active fourth quarter with a number of eagerly
anticipated IPOs.
Tags: News
|
August 2013 IPO Market Review
September 5, 2013 4:23
PM
The August 2013 IPO market flourished in the first half of the
month before almost completely shutting down, as it traditionally
does, during the last two weeks. The month produced 15
IPOs—almost 70% above the August average over the past 10
years and equal to the monthly tally in August 2007, the recent
high point for August IPOs. Since 2000, there have been a total of
only four IPOs in the two weeks prior to Labor Day.
Gross proceeds were $3.11 billion in August, bringing
year-to-date gross proceeds to $22.53 billion.
The number of IPOs in 2013 year-to-date has now passed the
full-year total of 97 IPOs in 2011 and is only one shy of the 102
IPOs in all of 2012. With the arrival of fall, the IPO market
appears poised to resume its brisk pace, with a number of companies
already on the September calendar.
The IPO market remains dominated by emerging growth companies
(EGCs), accounting for 78% of all IPOs in the first eight months of
2013—similar to the 76% market share for EGC IPOs in 2012
following the enactment of the JOBS Act in April 2012.
VC-backed and PE-backed company IPOs accounted for 42% and 33%,
respectively, of all IPOs in the first eight months of the
year.
After the surge in life sciences IPOs over the first seven
months of 2013, August saw only a trio of new life sciences
offerings—two pricing below the initial price range. Filing
activity for life sciences companies, however, remains brisk with
six new filings in August. Year-to-date there have been 31 life
sciences IPOs—31% of the year's total.
The median deal size of $101.2 million for the first eight
months of 2013 was 7% higher than the $94.3 million median in
full-year 2012. The median deal size for VC-backed companies was
$77.8 million—the lowest level since the $72.0 million median
in 2006—while the median deal size for non-VC backed
companies was $217.5 million—almost a third higher than the
2012 figure. The median deal size for EGCs, at $80.5 million, was
less than a fifth of the $436.3 million median deal size for other
companies.
The median annual revenue of IPO companies in 2013 remains well
below the 2012 level, in part due to the high percentage of life
sciences companies going public. Median annual revenue decreased
37%, from $133.6 million in 2012 to $84.3 million in 2013 to
date—the lowest level since the $74.5 million median in 2007.
Life sciences companies going public so far this year had median
annual revenue of just $15.5 million. EGCs completing IPOs
year-to-date had median annual revenue of $53.4 million, compared
to $2.36 billion for other companies.
The average IPO in the first eight months of 2013 saw a 17%
first-day gain from its offering price—just eclipsing the
average 16% first-day gain for full-year-2012. Year-to-date, 29
companies—29% of the total—have produced a first-day
gain of at least 25%. Eleven IPOs enjoyed a first-day gain of at
least 50%, including five IPOs by life sciences companies. On the
other end of the spectrum, 24 IPOs have been "broken"
(IPOs whose stock closes below the offering price on their opening
day), compared to 20% in all of 2012. Only two of the 14 IPOs in
August 2013 were broken, with a further one flat on its first
day.
The percentage of profitable companies going public has drifted
down from 55% in 2012 to 46% in 2013 year-to-date, with only 16% of
the life sciences companies completing IPOs showing a profit in
their most recent fiscal year.
At August month-end, the average 2013 IPO was trading up 33%
from its offering price, and 46% of the year's IPOs were
trading 25% or more above their offering price, including 28% up
more than 50% from their offering price. The average IPO in the
first eight months of 2013 has gained 13% from the first-day close
to August month-end.
August IPO activity consisted of offerings by the following
companies listed in the order they came to market:
- Athlon Energy, a private equity–backed
independent oil and gas exploration and production company
operating in the Permian Basin, priced at the top of the range and
saw a first-day gain of 38%.
- Control4, a provider of home automation and
control solutions, priced at the midpoint of the range and ended
its first day up 25%.
- Marrone Bio Innovations, a producer of
bio-based pest management and plant health products, priced an IPO
upsized by 13% below the range and produced a first-day gain of
15%.
- YuMe, a provider of digital video brand
advertising solutions, priced below the range and ended its first
day flat.
- Fox Factory Holding, a private
equity–backed designer, manufacturer and marketer of
high-performance suspension products used on mountain bikes and
off-road vehicles, priced at the top of the range and saw a
first-day gain of 24%.
- Intrexon, which is developing synthetic
biology technologies to improve drugs and food, priced an IPO
upsized by 20% at the high end of the range and ended its first day
up 55%.
- Cvent, a provider of a cloud-based enterprise
event management platform, priced above the range and enjoyed a
first-day gain of 57%.
- Frank's International, a global provider
of tubular services to the oil and gas industry, priced above the
range and gained 20% on its first day.
- MiX Telematics, a global provider of fleet and
mobile asset management solutions delivered as
software-as-a-service, priced at the top of the range and saw a
first-day gain of 13%.
- Stock Building Supply Holdings, a private
equity–backed diversified lumber and building materials
distributor and solutions provider, priced an IPO downsized by 21%
below the range but produced a first-day gain of 3%.
- China Commercial Credit, which provides loans
and loan guarantee services to small to-medium sized businesses in
the Jiangsu Province of China, priced an IPO downsized by almost
50% and declined 2% on its first day only to double in trading the
following day to end its second trading day 95% above its offering
price.
- Envision Healthcare Holdings, a private
equity–backed provider of physician-led, outsourced medical
services, priced an IPO upsized by 20% at the top of the range and
saw a first-day gain of 9%.
- Bermuda-based Third Point Reinsurance, a
private equity–backed property and casualty reinsurer, priced
an IPO trimmed by less than 1% at the low end of the range and
traded up 4% on the first day.
- Sophiris Bio, a clinical-stage
biopharmaceutical company focused on developing innovative products
for the treatment of urological diseases, priced an upsized IPO at
a lower revised price maintaining expected proceeds, and declined
17% on its first day.
- Regado Biosciences, a biopharmaceutical
company focused on the discovery and development of novel,
first-in-class, actively controllable antithrombotic drug systems
for acute and sub-acute cardiovascular indications, priced an
upsized IPO below a downwardly revised price and saw a first-day
gain of 18%.
Please click here to carry on reading this article in
full
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
|